enVVeno Medical Corp
NVNO0.933USD
-0.001-0.16%
收盘 09/19, 16:00（美东）报价延迟15分钟
17.96M总市值
亏损市盈率 TTM
关于 enVVeno Medical Corp 公司
enVVeno Medical Corporation 是一家后期临床医疗技术公司。该公司专注于生物假体（组织型）解决方案的进步，以提高静脉疾病治疗的护理标准。该公司正在为患有腿部深静脉系统严重慢性静脉功能不全 (CVI) 的患者开发手术和非手术置换静脉瓣膜。该公司的主打产品 VenoValve 是一种基于猪的置换静脉瓣膜，通过手术植入腿部深静脉系统以治疗严重的 CVI。VenoValve 是通过大腿上部 5 到 6 英寸的切口在开放式手术中植入患者的股静脉的。VenoValve 正在美国外科抗反流静脉瓣膜内置假体 (SAVVE) 临床试验中进行评估。该公司还在开发第二种产品 enVVe，这是一种非手术、经导管置换静脉瓣膜。
公司简介
公司代码NVNO
公司名称enVVeno Medical Corp
上市日期May 31, 2018
CEOMr. Robert A. Berman
员工数量37
证券类型Ordinary Share
年结日May 31
公司地址70 Doppler
城市IRVINE
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编92618
电话19492612900
网址https://envveno.com/
公司代码NVNO
上市日期May 31, 2018
CEOMr. Robert A. Berman
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
97.44K
-4.79%
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
10.36K
-7.17%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Jennifer Bright
Ms. Jennifer Bright
Chief Financial Officer
Chief Financial Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
97.44K
-4.79%
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
10.36K
-7.17%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月23日 周六
更新时间: 8月23日 周六
持股股东
股东类型
持股股东
持股股东
占比
Kingdon Capital Management, L.L.C.
7.06%
Perceptive Advisors LLC
6.68%
The Vanguard Group, Inc.
3.63%
Nantahala Capital Management, LLC
3.09%
Westside Investment Management, LLC
1.45%
其他
78.09%
持股股东
持股股东
占比
Kingdon Capital Management, L.L.C.
7.06%
Perceptive Advisors LLC
6.68%
The Vanguard Group, Inc.
3.63%
Nantahala Capital Management, LLC
3.09%
Westside Investment Management, LLC
1.45%
其他
78.09%
股东类型
持股股东
占比
Hedge Fund
11.63%
Investment Advisor
7.83%
Private Equity
6.81%
Investment Advisor/Hedge Fund
2.66%
Research Firm
1.12%
Individual Investor
0.81%
Venture Capital
0.09%
其他
69.05%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
75
3.80M
19.76%
-3.06M
2025Q1
73
3.82M
21.80%
-3.21M
2024Q4
75
4.44M
25.31%
-1.95M
2024Q3
71
5.27M
30.14%
+688.15K
2024Q2
65
3.79M
29.68%
-1.51M
2024Q1
67
4.10M
32.04%
-789.97K
2023Q4
59
4.71M
36.59%
+2.14M
2023Q3
57
2.68M
28.24%
-1.00M
2023Q2
55
2.71M
28.61%
-1.36M
2023Q1
54
2.76M
29.13%
-1.37M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Kingdon Capital Management, L.L.C.
859.26K
4.9%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
600.91K
3.43%
+11.77K
+2.00%
Mar 31, 2025
Nantahala Capital Management, LLC
594.66K
3.39%
-2.26K
-0.38%
Mar 31, 2025
Westside Investment Management, LLC
259.05K
1.48%
+54.02K
+26.35%
Mar 31, 2025
UBS O'Connor LLC
296.03K
1.69%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
197.30K
1.13%
+15.56K
+8.56%
Mar 31, 2025
J.P. Morgan Securities LLC
194.21K
1.11%
-75.83K
-28.08%
Mar 31, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
公告日期
类型
比率
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
